可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Miyamoto M,Tayama T,Yamaguchi S,et al.Improvement of walking disturbance by beraprost sodium in rat femoral artery occlusion models[J].Eur J Pharmacol,2006,545(2-3):173-176.
[2]Tamura M, Kurumatani H,Matsushita T.Comparative effects of beraprost,a stable analogue of prostacyclin, with PGE1,nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension[J]. Prostaglandins Leukot Essent Fatty Acids,2001,64(3):197-202.
[3]Ohta S,Nakamuta M,Fukushima M,et al.Beraprost sodium,a prostacyclin(PGI2)analogue, ameliorates concanavalin A-induced liver injury in mice[J].Liver International,2005,25(5):1061-1068.
[4]Yamada M,Sasaki R,Sato N,et al.Amelioration by beraprost sodium,aprostacyclin analogue,of established renal dysfunction in rat glomerulonephritis model[J].Eur J Pharmacol,2002,49(1-2):167-176.
[5]Yamada M,Sasaki R, Sato N,et al.Effects of beraprost sodium,an oral prostaglandin I2 analog, on hemostatic factors and inflammation in chronic peritoneal dialysis patients[J].Perit Dial Int,2009,29(2):178-181.
[6]Murry CE,Jennings RB,Reimer KA,et al.Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium[J].Circulation,1986,74(5):1124-1136.
[7]寇俊杰,王爱华,卫丹,等.IPC和缬沙坦在心肌缺血/再灌注损伤中的作用[J].心脏杂志,2009, 21(1):11-17.